CDK1 and cancer: We investigated the hypothesis that CDK1 and HSP90 signaling overlaps in the regulation of HIF1α, and combination treatment to target both CDK1 and HSP90 may lead to enhanced inhibitory effects towards HIF1α expression and function as well as improved anti-cancer efficacy.